Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Evaluating the Safety, Tolerability, and Potential Efficacy of IBI315, an Anti-HER2/PD-1 Bi-specific Antibody in Patients With HER2-expressing Advanced Solid Tumor

Next Previous
Search
Trial Profile

A Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Evaluating the Safety, Tolerability, and Potential Efficacy of IBI315, an Anti-HER2/PD-1 Bi-specific Antibody in Patients With HER2-expressing Advanced Solid Tumor

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidasimtamab (Primary) ; Antineoplastics
  • Indications Solid tumours
  • Focus First in man; Pharmacokinetics
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 22 Oct 2023 Status changed from recruiting to completed.
    • 28 Sep 2021 According to an Innovent Biologics media release, preliminary results from phase 1a study were presented in an oral presentation at the 2021 Annual Meeting of Chinese Society of Clinical Oncology (CSCO).
    • 28 Sep 2021 Preliminary results (n=27, data cutoff date of May 25, 2021) of the Phase Ia study published in an Innovent Biologics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top